Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Sorafenib PK in Patients With Advanced HCC and Child-Pugh B
NCT04051853 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · PHASE2 · terminated · last registry update 2019-08-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual.” | – | Registry record, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RAF1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-07-07Results posted on the registry: National Cancer Institute (NCI), Asparaginase + Bortezomib (NCT01371981)
- 2020-06-26Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Sorafenib (NCT02576509)
- 2020-06-22Results posted on the registry: Beth Israel Deaconess Medical Center, Sorafenib (NCT00813293)
- 2020-05-14Phase 3 first posted: First Affiliated Hospital of Zhejiang University, Sorafenib (NCT04387695)
- 2020-04-14Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AK105 Injection + Anlotinib Hydrochloride Capsules (NCT04344158)
- 2020-02-20Results posted on the registry: AVEO Pharmaceuticals, Inc., Tivozanib hydrochloride + Sorafenib (NCT02627963)
- 2019-09-25Phase 3 first posted: Sun Yat-sen University, TACE+sorafenib (NCT04103398)
- 2019-09-20Results posted on the registry: National Cancer Institute (NCI), Sorafenib Tosylate (NCT02066181)
- 2019-07-31Phase 3 first posted: Bristol-Myers Squibb, Nivolumab + Ipilimumab (NCT04039607)
- 2019-07-30Results posted on the registry: Astex Pharmaceuticals, Inc., SGI-110 (NCT01752933)
- 2019-07-26Results posted on the registry: Academic and Community Cancer Research United, Clobetasol Propionate + Regorafenib (NCT02368886)
- 2019-05-31Phase 3 first posted: Global Coalition for Adaptive Research, Temozolomide + Lomustine (NCT03970447)
- 2019-05-17Results posted on the registry: Eli Lilly and Company, Ramucirumab + Placebo (NCT02435433)
- 2019-05-10Results posted on the registry: Case Comprehensive Cancer Center, Regorafenib + Gemcitabine Hydrochloride (NCT02383433)
- 2019-02-15Results posted on the registry: University of Nebraska, Sorafenib (NCT00496756)
- 2019-02-04Phase 3 first posted: Institut du Cancer de Montpellier - Val d'Aurelle, Regorafenib + Irinotecan (NCT03829462)
- 2018-12-21Results posted on the registry: National Cancer Institute (NCI), Sorafenib Tosylate (NCT00390325)
- 2018-12-05Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., SHR-1210 + Apatinib (NCT03764293)
- 2018-11-28Phase 3 first posted: Exelixis, Cabozantinib + Cabozantinib (NCT03755791)
- 2018-08-23Results posted on the registry: Thomas Jefferson University, Ascorbic Acid + Sorafenib + Sorafenib (NCT01754987)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision